Autism spectrum disorders, endocrine disrupting compounds, and heavy metals in amniotic fluid:a case-control study by Long, Manhai et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Autism spectrum disorders, endocrine disrupting compounds, and heavy metals in
amniotic fluid
Long, Manhai; Ghisari, Mandana; Kjeldsen, Lisbeth; Wielsøe, Maria; Nørgaard-Pedersen,








Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Long, M., Ghisari, M., Kjeldsen, L., Wielsøe, M., Nørgaard-Pedersen, B., Mortensen, E. L., ... Bonefeld-
Jørgensen, E. C. (2019). Autism spectrum disorders, endocrine disrupting compounds, and heavy metals in
amniotic fluid: a case-control study. Molecular Autism, 10, [1]. https://doi.org/10.1186/s13229-018-0253-1
Download date: 03. Feb. 2020
RESEARCH Open Access
Autism spectrum disorders, endocrine
disrupting compounds, and heavy metals
in amniotic fluid: a case-control study
Manhai Long1* , Mandana Ghisari1, Lisbeth Kjeldsen1, Maria Wielsøe1, Bent Nørgaard-Pedersen2,
Erik Lykke Mortensen3, Morsi W. Abdallah4 and Eva C. Bonefeld-Jørgensen1,5
Abstract
Background: Evidence has indicated that some non-inherited factors such as exposure to environmental pollutants
are associated with neurodevelopment disorders like autism spectrum disorder (ASD). Studies report that endocrine
disrupting compounds (EDCs), including polychlorinated biphenyls, organochlorine pesticides, perfluoroalkyl
substances (PFAS), and some metals, have adverse effects on the fetal neurodevelopment. The aim of this study
was to measure the amniotic fluid (AF) levels of EDCs and metals as well as the receptor transactivities induced by
AF and investigate the possible link between prenatal exposure to EDCs and heavy metals and ASD risk.
Methods: In this case-control study, we included AF samples of 75 ASD cases and 135 frequency-matched controls
and measured the levels of the endogenous sex hormones, PFAS, and elements including heavy metals. The
combined effect of endogenous hormones and EDCs on the receptor of estrogen (ER), androgen (AR), aryl
hydrocarbon (AhR), and thyroid hormone-like activity were also determined and expressed as receptor ligand
equivalents. We assessed the associations of AF levels of chemicals, sex hormones, and receptor activities with ASD
risk using unconditional logistical regression analyses. To control for multiple comparisons, the false discovery rate
(FDR) was used and q values less than 0.25 were designated as statistical significance.
Results: PFAS and metals were detectable in AF samples. The ASD cases had significantly lower AF levels of PFAS
than controls, and the adjusted odds ratio (OR) was 0.410 (95% CI 0.174, 0.967; p = 0.042; FDR qvalue = 0.437) for
perfluorooctane sulfonate (PFOS). The principal component, including PFAS congeners, copper, iron, and estrogenic
activity, was significantly inversely associated with ASD risk (adjusted OR = 0.100; 95% CI 0.016, 0.630; p = 0.014; FDR
qvalue = 0.098).
Testosterone level in AF weakly associated with ASD risk (adjusted OR = 1.002; 95% CI 1.000, 1.004; p = 0.05).
However, after multiple comparison correction, the association was not significant (FDR qvalue = 0.437). No
significant associations between AF-induced receptor transactivities and ASD risk were observed. The adjusted OR
was 2.176 (95%CI 0.115, 41.153) for the ratio of the combined androgenic activity to combined estrogenic activity.
Conclusions: The presence of PFAS and heavy metals in AF indicates that they can cross the placenta. The inverse
association between levels of PFAS congeners in AF and ASD risk might relate to the weak estrogenic activities and
anti-androgenic activities of PFAS.
The observed tendency of positive association between the ratio of combined androgenic effect to the combined
estrogenic effect and ASD risk needs further studies to explore whether EDCs together with endogenous hormones
play a role in the development of ASD.
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Background
Autism spectrum disorder (ASD) is a group of heteroge-
neous neurodevelopmental disorders characterized by
qualitative impairments in social interaction, communi-
cation, and repetitive or stereotyped behavior [1]. Epi-
demiological studies indicate an increasing worldwide
prevalence of ASD during the last decades [2, 3]. In
Denmark, prevalence of ASD has increased between
1972 and 2007 and a recent estimate was approximately
0.74% [4].
The etiology of ASD is not fully clarified. Despite the
evidence of a genetic component [5], genetic factors can-
not fully explain ASD, and single gene and chromosomal
defects only account for a minority of ASD cases (10–
20%) [6, 7]. The accumulating evidence shows that some
non-inherited factors such as exposure to environmental
pollutants and neurotoxins are associated with ASD risk
[8–11]. Moreover, studies suggest that the endocrine sys-
tem plays a role in the etiology of ASD [12]. Autistic
traits were increased following prenatal exposure to ab-
normally high levels of testosterone caused by congenital
adrenal hyperplasia [13]. ASD was linked with elevated
fetal testosterone levels in amniotic fluid during routine
amniocentesis [14]. A study in 192 twins reported that
environmental factors accounted for 55% of the risk of
developing ASD compared with genetic factors account-
ing for 37% [15]. One review reported that 89% of the
included publications implicated an association between
environmental toxicants and ASD [16].
Children are vulnerable to the neurotoxic effects of
chemicals, especially during the prenatal period, when
there is an immature blood-brain barrier and neuronal
growth, migration, and myelination processes that occur
on a specific and rapid schedule [17, 18]. Moreover,
some toxic substances can pass through the placental
barrier and easily access the developing brain and inter-
fere with these important processes, possibly leading to
adverse outcomes [17]. Some environmental pollutants
can interfere with the endocrine system acting as endo-
crine disrupting compounds (EDCs), including persistent
organic pollutants (POPs) such as polychlorinated biphe-
nyls (PCBs), organochlorine pesticides (OCPs), polybro-
minated diphenyl ethers (PBDEs), dioxins [19–22],
perfluoroalkyl substances (PFAS) [23, 24], and
non-persistent compounds like bisphenol A [25–27].
EDCs may alter endogenous axes and interfere with
steroid-dependent neurodevelopment and modify the
ASD risk [28, 29]. A variety of EDCs in blood and urine
samples of pregnant women were reported to be related
to children’s autistic behavior [12]. Animal studies re-
ported that PFAS had adverse effects on neurodevelop-
ment [30, 31]. A Korean study showed that mothers of
children with ASD had higher exposure to PBDEs, PCBs,
bisphenol A, and dioxins through canned food, plastics,
waste incinerators, old electronics, microwavable food,
and textiles compared to mothers with typically develop-
ing children [32]. Studies have linked autistic behavior
with prenatal exposure to the organophosphate insecti-
cide chlorpyrifos [33] and phthalates [34]. In addition, a
study reported that gestational exposure to the OCPs,
dicofol and endosulfan, was associated with an increased
risk of ASD [9]. Parental occupational exposure to che-
micals such as solvent xylene was reported to be associ-
ated with ASD [35]. Some elements and heavy metals,
such as iron (Fe), copper (Cu), zinc (Zn), selenium (Se),
iodine (I), arsenic (As), mercury (Hg), cadmium (Cd),
lead (Pb), and manganese (Mn), might impact on the de-
velopment of the nervous system [29, 36–41]. Perinatal
exposure to air pollutants, including Hg, Pb, and Mn,
was linked to an increased risk of ASD with stronger as-
sociations for boys [42].
Humans are exposed to dozens of potential EDCs
across the lifespan. The fetus and infant have relatively
greater exposure to some EDCs and are more vulnerable
than adults. Multiple EDCs may have a combined effect,
and the health-related consequences of EDC mixtures
are thus of concern. An approach to assess the com-
bined EDC effects of complex EDC mixtures is to meas-
ure the overall impact of all EDCs present in a sample
on the hormone receptor-mediated transactivation such
as measurement of estrogen receptor (ER) transactivity,
androgen receptor (AR) transactvity, thyroid hormone
(TH) function, and aryl hydrocarbon receptor (AhR)
transactivity in the biological samples using ex vivo
mammalian cell culture systems [43, 44].
The matrices for prenatal exposure biomarkers are
often maternal blood and umbilical cord blood, but cor-
relations with measures in fetal compartments can be
low. In practice, umbilical cord blood is obtainable only
at birth, but the expected vulnerable time window for
many health outcomes is often earlier in the pregnancy
(e.g., during organogenesis). Amniotic fluid (AF) offers
another possible fetal matrix, but samples are most often
only available from amniocentesis indicated by advanced
maternal age or by prenatal diagnostics of chromosomal
abnormalities and severe malformations. It is a major
advantage, however, that amniocentesis is usually per-
formed within the second trimester (gestational weeks
13 to 28), which may be closer to the expected vulner-
able period for many adverse outcomes. It is suggested
that contaminant concentrations in AF during the first
half of pregnancy (before 20 weeks of gestation) can be a
suitable proxy measure of intra-fetal contaminant expos-
ure, because AF is derived mainly from fetal blood and
fluids during this period [45]. Studies have shown that
the risk of autism tends to be higher upon exposures
within the first half of pregnancy [46]. Although contam-
inants in maternal blood or umbilical cord blood are
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used as a proxy for fetal exposure, little is known about
the actual exposure level of the fetus.
The purpose of this study was using AF to (1) measure
EDCs and elements including heavy metals, (2) determine
the receptor transactivities induced by EDCs, and (3) per-
form a case-control study to investigate the hypothesis
that in utero exposure to EDCs and heavy metals is associ-
ated with an increased risk for ASD. In addition, principle
component analysis was used to identify the potential
underlying components of substances in AF to explore the
effect of substance mixture on ASD risk.
Methods
Study population and sample selection
Figure 1 presents the case and control selection process.
Study subjects were initially selected from a population
of singleton births between 1982 and 1999 with AF sam-
ples available as part of the Historic Birth Cohort (HBC)
stored at the Statens Serum Institute (SSI) in
Copenhagen, Denmark [47]. The HBC is based on a col-
lection of antenatal biological samples obtained during
screening/diagnostic procedures performed mainly in
three Danish regions. The collection of samples goes
from the late 1970s until 2004 and includes more than
100,000 samples of AF, bloodspots, and maternal serum
samples (Fig. 1) [14, 48]. The AF samples from the HBC
were centrifuged after routine screening or diagnostic
amniocentesis, and samples were kept frozen at − 20 °C
until further analyzed [49]. The Danish nation-wide
health registers were employed to follow-up individuals
in the HBC until 2009. All psychiatric diagnoses were
identified utilizing the Danish Psychiatric Central Regis-
ter (DPCR) which has high diagnosis validity of infantile
autism diagnoses [50]. All singleton ASD cases born
during 1982–1999 were identified according to the
International Classification of Diseases (ICD)-8 codes
299.xx up to 1993 and ICD-10 codes DF84.xx since
1994. Furthermore, the Danish National Hospital Regis-
ter (DNHR) primary diagnoses [51] were applied to
complement diagnoses of congenital malformations and
other psychiatric comorbidities. The birth record data of
the study subjects were retrieved from the Danish
Fig. 1 Flow chart of autism disorders (ASD) and controls selection process
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medical birth registry [52]. The controls were non-ASD
individuals randomly retrieved from the HBC and
frequency-matched with cases on gender and year of
birth [47].
The present study aims to examine whether EDCs in
AF influence individuals diagnostics with ASD later in
life using the case-control design. We first performed a
pilot study on pooled AF to establish methods for the
EDC-receptor function analyses and measurement of
POPs such as PCBs, OCPs, and PFAS as well as ele-
ments including heavy metals. The pilot study showed
that the levels of lipophilic POPs (PCBs, OCPs, dioxins,
PBDEs) in AF samples were below the detection limits
while PFAS, elements/metals, and AF-induced combined
receptor transactivities could be detected in AF samples.
Therefore, 1032 individual AF samples including 332
ASD cases and 700 controls were obtained from the SSI
and stored at − 20 °C in Centre for Arctic Health & Mo-
lecular Epidemiology, Department of Public Health, Aar-
hus University, Denmark, for the determination of
PFAS, elements, and the combined ex vivo receptor
transactivities (ER, AR, AhR, and TH). Since many pa-
rameters had to be determined in each AF sample, the
first selection of samples was based on available samples
having adequate volume. AF samples of ASD cases and
controls with adequate volume were thus selected and
frequency-matched by gender and year of birth. Due to
the possible influence of maternal age on ASD, the ASD
cases and controls were further matched by maternal
age with approximately 1:2 case-control match (Fig. 1).
Changes in concentrations of analytes over prolonged
times are a known issue [53], and the way the samples
were stored pre- and post-1993 was different.
Baron-Cohen reported the evidence of evaporation and
the concentrations of various analytes of pre-1993 sam-
ples were higher than those of post-1993 samples [14].
In addition, after 1993, the timing of amniocentesis in
Denmark was standardized using ultrasound to mark
gestational age and diagnostic information after 1993 be-
came much more reliable by switching to ICD-10 [50,
54]. Therefore, the present study was restricted to indi-
viduals born between 1993 and 1999. However, several
samples were stored in tubes with blue rubber caps con-
taining cell toxic compounds affecting cell culture
growth. Those samples were excluded from the present
study. Finally, 75 ASD cases (62 boys, 13 girls) and 135
frequency-matched controls (109 boys, 26 girls) born
during 1995–1999 with adequate AF volume were in-
cluded in the study (Fig. 1).
Perfluoroalkyl substances (PFAS) measurements
The concentrations of PFAS in AF were measured at the
Institute for Environmental Science, Aarhus University,
Denmark. The extraction method was based on ion
pairing as described previously [55]. Six perfluorosulfo-
nated acids (PFSA) and eight perfluorocarboxylated
acids (PFCA) were determined by liquid
chromatography-tandem mass spectrometry
(LC-MS-MS) with electrospray ionization (ESI) [56].
The measured PFSA were perfluorooctane sulfonate
(PFOS), perfluoroheptane sulfonate (PFHpS), perfluoro-
butane sulfonate (PFBS), perfluorohexane sulfonate
(PFHxS), perfluorodecane sulfonate (PFDS), and per-
fluorooctane sulfonamide (PFOSA). The sum of PFOS,
PFHpS, PFBS, PFHxS, PFDS, and PFOSA was given as
∑PFSA. The measured PFCA were perfluorooctanoic
acid (PFOA), perfluorohexanoic acid (PFHxA), perfloro-
heptanoate (PFHpA), perfluorononanoic acid (PFNA),
perfluorodecanoic acid (PFDA), perfluoroundecanoic
acid (PFUnA), perfluorododecanoic acid (PFDoA), and
perfluoro-n-pentanoic acid (PFPeA). The sum of PFOA,
PFHxA, PFHpA, PFNA, PFDA, PFUnA, PFDoA, and
PFPeA was given as ∑PFCA. Half of the limit of quanti-
fication values were used for concentrations below the
limit of quantification (Additional file 1).
Measurement of elements and metals
The concentrations of 59 elements and heavy metals in
AF were determined using inductively coupled plasma
mass spectrometry (ICP-MS) after dilution 20 times with
5% nitric acid at the Institute for Bioscience-Arctic Re-
search Centre, Aarhus University, Denmark. The quality
was ensured by participation in the Quality Assurance of
Information in Marine Environmental monitoring
(QUASIMEME) inter-laboratory comparison program
[57]. The detection limits of measured elements were
obtained as three times the standard deviation of blind
(acid alone). Half of the detection limit values were used
for concentrations below the detection limit
(Additional file 2).
Measurement of endogenous sex hormones
The endogenous sex hormone levels in AF were deter-
mined by solid phase fluoroimmunoassays. The DELFIA®
Estradiol kit and Testosterone kit (PerkinElmer Life and
Analytical Sciences, Wallac Oy, Turku, Finland) [58]
were used to measure the levels of estrogen
17β-Estradiol (E2) and androgen testosterone, respect-
ively, at the Centre of Arctic Health & Molecular Epi-
demiology, Department of Public Health, Aarhus
University, Denmark. The DELFIA kits offer a faster
method for measuring estradiol and testosterone with
adequate sensitivity compared to radioimmunoassays
[59]. The detection limit was 13.62 pg/mL and 115.4 pg/
mL for E2 and testosterone, respectively. The intra-assay
and inter-assay coefficient of variation was 10.0% and
9.7% for E2 and 5.7% and 8.4% for testosterone,
respectively.
Long et al. Molecular Autism            (2019) 10:1 Page 4 of 19
Measurement of receptor transactivities induced by AF
To evaluate the potential of the compounds/molecules in
AF to interfere with the estrogen receptor (ER), androgen
receptor (AR), and aryl hydrocarbon receptor (AhR) trans-
activation, the luciferase reporter gene transactivities (tact)
of these receptors (ER-tact, AR-tact, and AhR-tact) were
determined. For thyroid hormone (TH)-related action, the
proliferative effect (TH-PE) of AF was determined using a
TH-dependent GH3 cell proliferation assay (T-screen
assay) at the Centre for Arctic Health & Molecular Epi-
demiology, Department of Public Health, Aarhus Univer-
sity, Denmark. The established luciferase reporter gene
bioassays [20, 27, 60] and the T-screen assay [21] have
been described earlier in detail.
The AF-induced ER-tact was determined by direct ex-
posure of the stably transfected MVLN cells to 6.25 μl
AF dissolved in 100 μl of culture medium (CD-FCS
DMEM). In parallel, an eight-point E2 series (3.1–300
pM) was included as a positive control and used for es-
tradiol equivalent (ER-EEQ) calculation.
The AF-induced AR-tact was determined by direct ex-
posure of transiently transfected CHO-K1 cells to 5 μl
AF dissolved in 100 μl of culture medium (DMEM/F12
+ 10% CD-FCS). In parallel, an eight-point dihydrotes-
tosterone (DHT) series (2–200 pM) was included as a
positive control and used for calculation of the androgen
equivalent (AR-AEQ).
The TH-disrupting potential of AF (TH-PE) was ana-
lyzed in the T-screen assay by exposing the GH3 cells to
14 μl of AF in 200 μl thyroid hormone-depleted CD-FCS
DMEM. In parallel, an eight-point triiodothyronine (T3)
series (10–10,000 pM) was included as a positive control
and for calculation of the thyroid equivalent (T3-ThEQ).
We measured the AhR transactivity (AhR-tact) of AF
by exposure of Hepa1.12cR cells to an AF extract. The
AF extracts were prepared as follows: 500 μl AF was ex-
tracted on a solid phase extraction (SPE) column (Dis-
covery C18, Sigma-Aldrich), eluted with hexane and
evaporated to near dryness. The SPE extract of AF was
dissolved in 1 μl DMSO, and 400 μl of culture medium
(alpha MEM) was added. The cells were exposed to
100 μl/well of this solution of AF extract, and the
AhR-tact was determined. As procedural blank, 500 μl
distilled water was extracted, processed, and analyzed in
the same way as the AF samples. In parallel, a
nine-point 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin
(TCDD, potent AhR ligand) series (2–5000 pM) was in-
cluded as a positive control and used for calculation of
the AhR-TCDD equivalent (AhR-TEQ).
Calculation of receptor ligand equivalent (EQ)
The combined effect on the hormone receptors induced
by the endogenous hormones and EDCs present in AF
was calculated as the corresponding receptor ligand
equivalent (EQ). Table 1 shows an explanation of mea-
sured receptor transactivities induced by AF and calcula-
tion of EQ. Briefly, the receptor ligand EQ was
calculated by interpolation of the measured transactivity
value of ER-tact, AR-tact, and TH-PE on the corre-
sponding ligand dose-response four-parameter sigmoidal
Hill curve and expressed as ER-EEQ (pg E2/mL AF),
AR-AEQ (pg DHT/mL AF), and T3-ThEQ (ng T3/mL
AF), respectively. The integrated xenoestrogenic effect
induced by EDCs alone was estimated by subtracting
concentration of endogenous E2 from ER-EEQ and
expressed as EDC-EEQ (pg E2/mL AF). For those
ER-EEQ values less than the levels of E2, half of E2 de-
tect limit was given as their EDC-EEQ values. We did
not measure the DHT level but the testosterone level.
The literature reported that almost 10% of the testoster-
one is converted to DHT [61]. In our lab, we observed
that the potential of testosterone activating AR is 10 times
less than DHT; this is similar to a previous study [62].
Thus, we estimated the level of endogenous DHT to be
10% of measured testosterone and subsequently the
EDC-induced xenoandrogenic effect was obtained by sub-
tracting the estimated endogenous DHT level from
AR-AEQ and expressed as EDC-AEQ (pg DHT/mL AF)
(Table 1). For those AR-AEQ values lower than levels of
DHT, 10% of half testosterone detect limit was given as
their EDC-AEQ values. To explore whether the endogen-
ous sex hormones and/or EDCs influence the balance be-
tween androgenic effect and estrogenic effect, the ratio of
AR-AEQ to ER-EEQ (AR-AEQ/ER-EEQ) and ratio of
EDC-AEQ to EDC-EEQ (EDC-AEQ/EDC-EEQ) were fur-
ther calculated. AR-AEQ/ER-EEQ represents the propor-
tion of total combined androgenic effect to the total
combined estrogenic effect. EDC-AEQ/EDC-EEQ reflects
the proportion of EDC-induced androgenic effect to
EDC-induced estrogenic effect.
The TCDD equivalent (AhR-TEQ) values of the AF ex-
tracts and procedural blank were estimated by interpolation
of their AhR-tact values on the TCDD dose-response
three-parameter sigmoidal Hill curve. The final net AhR–
TEQ of AF (pg TCDD/mL AF) was obtained by subtracting
the procedure blank TEQ value (Table 1).
Statistical analysis
Only the chemicals of interest and receptor transactiv-
ities that were detectable in at least 10% of the AF sam-
ples were included in the statistical analyses. Because
not all biomarkers were detected in all AF samples and
data were skewed, we compared the differences of ex-
posure biomarkers between the ASD cases and controls
using the non-parametric Mann-Whitney test.
We used Spearman’s correlation analysis to analyze
the correlation of PFAS, elements, receptor transactiv-
ities, and potential confounders.
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To analyze the association of prenatal EDC exposure
and ASD risk, unconditional logistical regression ana-
lysis was used to estimate the odds ratio (OR) and 95%
confidence interval (95% CI). The levels of PFAS, ele-
ments, and receptor transactivities were included as con-
tinuous variables into the model with and without
potential confounders.
The change in estimate principle [63] was used to
identify the confounders using a cutoff of 5%. Poten-
tial confounders available for this analysis included
birth year and gender of child, maternal age at child
birth, paternal age at child birth, birth weight, gesta-
tional age at birth, gestational week at sampling,
Apgar score, and parity based on a priori
consideration of the research design and ASD risk
factors [64–66]. Given that ASD risk is also driven by
genetic factors, we further adjusted for congenital
malformation.
Twenty-nine individual exposure variables were de-
tected in more than 10% of samples, and multiple com-
parisons were performed. We controlled for multiple
comparisons using false discovery rate (FDR; qvalue) cor-
rection as suggested by Benjamini-Hochberg [67, 68].
Since the present study is the first study to explore the
associations of autism risk with chemicals and
AF-induced receptor transactivity, a false discovery rate
of 0.25 (FDR qvalue < 0.25) was used as a significant level
for the multiple comparison correction [69].
Table 1 Explanation of measured receptor transactivities induced by amniotic fluid (AF) and receptor ligand equivalent calculation
Abbreviations Explanation Example of calculation
ER-tact Luciferase reporter gene transactivity of estrogen receptor (ER)
ER-EEQ The combined effect on ER induced by the combination of endogenous estrogen and
xeno-estrogens (EDCs) given as estradiol equivalent
• ER-tact of AF: 2.51
• Interpolation of ER-tact onto E2 dose-
response curve
• ER-EEQ = 247.60 pg E2/ml AF
EDC-EEQ The integrated estrogenic effect induced by xeno-estrogens (EDCs) alone given as estra-
diol equivalent
• Endogenous E2: 230.23 pg/ml
• (ER-EEQ) − E2 = 247.60 − 230.32 = 17.28 E2
pg/ml AF
AR-tact Luciferase reporter gene transactivity of androgen receptor (AR)
AR-AEQ The combined effect on AR induced by the combination of endogenous androgens and
xeno-androgens (EDCs) given as androgen equivalent
• AR-tact of AF: 3.30
• Interpolation of AR-tact onto DHT dose-
response curve
• AR-AEQ = 63.50 pg DHT/ml AF
EDC-AEQ The integrated androgenic effect induced by xeno-androgens (EDCs) alone given as an-
drogen equivalent
• Testosterone: 470.12 pg/ml AF
• DHT: estimated DHT = 10% × 470.12 =
47.01 pg/ml AF




The proportion of total combined androgenic effect to the total combined estrogenic
effect
• AR-AEQ = 63.50 pg DHT/mlAF
• ER-EEQ = 247.60 pg E2/mlAF
• AR-AEQ/ER-EEQ = 63.50/247.60 = 0.256
EDC-AEQ/
EDC-EEQ
The proportion of EDC-induced androgenic effect to EDC-induced estrogenic effect • EDC-AEQ = 16.49 DHT/mlAF
• EDC-EEQ = 17.28 E2/mlAF
• EDC-AEQ/EDC-EEQ = 16.49/17.28 = 0.954
TH-PE Thyroid hormone-related proliferative effect
T3-ThEQ The combined proliferation effect (PE) of endogenous thyroid hormone and xeno-
thyroid hormone-like compounds (EDCs) given as thyroid equivalent
• TH-PE of AF: 4.56
• Interpolation of TH-PE onto T3 dose-
response curve
• T3-ThEQ = 3.53 ng T3/ml AF
AhR-tact Luciferase reporter gene transactivity of aryl hydrocarbon receptor (AhR)
AhR-TEQ The combined effect on AhR of dioxin-like compounds given as TCDD equivalent • AhR-tact of AF extraction: 5.67
• AhR-tact of blank: 4.75
• Interpolation of AhR-tact onto TCDD
dose-response curve = AhR-TEQ
• AhR-TEQ of AF extraction = 1.46 pg TCDD/
ml,
• AhR-TEQ of blank = 1.22 pg TCDD/ml
• Final AhR-TEQ = 1.46 − 1.22 = 0.24 pg
TCDD/ml AF
AF amniotic fluid, AEQ androgen equivalent, AR androgen receptor, AhR aryl hydrocarbon receptor, DHT dihydrotestosterone, EDCs endocrine disrupting
compounds, EEQ estradiol equivalent, ER estrogen receptor, E2 17 β-Estradiol, PE proliferation effect, TCDD 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin, TEQ TCDD
equivalent, T3 triiodothyronine, ThEQ thyroid equivalent
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ASD possesses gender difference with male preponder-
ance [70], and ASD is associated with a higher rate of
congenital malformation [71]. In addition, we suspected
possible modification effect of gender. We therefore fur-
ther performed the sensitivity analysis by stratifying on
children’s gender and excluding congenital malformation
diagnoses.
Principal component analysis
The use of a large number of individual parameters
would create a certain number of false positive results
when performing multiple comparisons. Principal com-
ponent analysis (PCA) is a powerful multivariate analyt-
ical tool and is applied to reduce a set of original
variables and to extract a smaller number of principal
components. Using PCA for data transformation is a
common ad hoc tool to deal with multicollinearity in
multiple regression models because the correlation be-
tween related compounds such as PFAS congeners exists
and this multicollinearity biases the estimation of indi-
vidual regression coefficients to cause misleading inter-
pretation of the effects of individual predictor variables
[72, 73]. PCA reduces the false positives by reducing the
number of variables [74]. Besides, people are exposed to
the mixture of different substances simultaneously, it is
important to assess the effect of actual effect of mixture
and PCA might provide the possibility to address this
issue. Therefore, we further used PCA to identify poten-
tial underlying components of levels of PFAS, metals,
and receptor transactivities in AF. By PCA, the corre-
lated variables are grouped together. The coefficients de-
fining these linear combinations, termed as “factor
loadings,” are the correlations of each input variables
with the component. The biomarkers which were detect-
able in more than 10% of all AF samples were input into
the model to extract principal components (PCs). The
number of PCs was extracted based on the eigenvalues
> 1 and Varimax rotation [75]. The Kaiser-Mayer-Olkin
(KMO) test (> 0.500) and Bartlett Test of Sphericity (p <
0.001) were used for testing the suitability of analysis.
All factors loading > |0.3| were used to identify the vari-
ables comprising a PC.
The difference of identified PCs between cases and
controls was analyzed by Mann-Whitney test. The asso-
ciation of identified PCs and ASD risk was also analyzed
by logistic regression model with and without adjust-
ment of potential confounders. FDR correction and sen-
sitivity analysis were also performed for the identified
principle components.
All statistical analyses were performed using SPSS ver-
sion 24.0 (SPSS Inc. Chicago, IL, USA) conducted at the
Centre of Arctic Health & Molecular Epidemiology, De-
partment of Public Health, Aarhus University, Denmark.
The statistical significance level was set to p ≤ 0.05. For
multiple comparison correction, the statistical level was
set to FDR qvalue < 0.25.
Results
Characteristics of the study population
Table 2 shows the descriptive characteristics of the study
population. Most children were male and born at term.
The majority of AF samples were obtained in gestational
week 15. More than 62% of mothers were carrying at
least two children. The demographics of cases and con-
trols were similar. The percentages of Apgar scores > 7
were above 98% both in case and control groups, indi-
cating that almost all participants in this study were
classified as healthy at birth. ASD cases were signifi-
cantly more co-diagnosed with congenital malformation
(29.30% vs. 8.10%, p < 0.0001).
Levels of perfluoroalkyl substances (PFAS)
PFOS, PFOSA, PFHxS, PFOA, and PFDoA were detect-
able in 46.6%, 35.2%, 4.50%, 81.8%, and 1.10% of the AF
samples, respectively; the remaining PFAS congeners
were under the limit of quantification (Additional file 1).
For the control group, no significant correlations be-
tween PFAS congeners and potential confounders were
observed, and PFOS was significantly correlated to
PFOA (r = 0.620, p < 0.0001), PFHxS (r = 0.330, p = 0.02),
and borderline to PFOSA (r = 0.300, p = 0.056) (data not
shown).
Cases significantly differed from controls with lower
levels of PFOS (p = 0.015) and ∑PFSA (p = 0.011) as well
as all the tested PFAS (∑PFSA+∑PFCA) (p = 0.021)
(Table 3). After false discovery rate correction, the signif-
icances persisted (FDR qvalue = 0.189, Table 3).
Levels of elements and heavy metals
Among the measured 59 elements and metals, 16 ele-
ments including iron (Fe), copper (Cu), zinc (Zn) and
selenium (Se) were detectable in all AF samples, while 8
elements, including mercury (Hg) and silver (Ag), were
not detectable in any AF samples. The metals of interest
such as chromium (Cr), lead (Pb), arsenic (As), manga-
nese (Mn), and cadmium (Cd) were detected in 98.9%,
34.1%, 22.7%, 18.2%, and 12.5% of the AF samples, re-
spectively (Additional file 2).
Similar levels of elements and heavy metals between
ASD cases and controls were observed (Table 3).
Levels of endogenous sex hormones and the combined
effect of endogenous hormones and EDCs on the
receptor transactivation
For the endogenous sex hormone levels, no significant
difference between ASD cases and controls was ob-
served. The ratio of testosterone to E2 was slightly
higher in ASD cases compared to controls (Table 4).
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The effect of AF samples on the receptor transactiva-
tion is given as the corresponding receptor ligand
equivalent (for detailed explanation see Table 1). We ob-
served that the combined effect of endogenous estrogen
and EDCs on ER (ER-EEQ) and EDC-induced xenoes-
trogenic effect (EDC-EEQ) was slightly lower in cases,
but the difference was not significant (Table 4). We ob-
served no significant differences between the ASD cases
and controls for the combined androgenic effect
(AR-AEQ) and neither for TH-like activity (T3-ThEQ)
and dioxin-like activity (AhR-TEQ) (Table 4).
Association of ASD risk and levels of chemicals
As given in Table 5, for the crude and adjusted data, we
observed an inverse association between PFOS level in
AF and ASD risk (adjusted OR 0.410, 95% CI 0.140–
0.967, p = 0.042) (Table 5). However, after false discovery
rate correction, the significance of PFOS disappeared
(FDR qvalue = 0.437, Table 5).
We observed no clear association for nutrient ele-
ments such as Fe, Cu, Zn, Se, and I with ASD risk
(Table 6). However, although no significant association
between toxic metals and ASD risk was observed, we
noticed that adjusted ORs were 1.496 (95% CI 0.924,
2.424; p = 0.101) for As and 1.300 (95% CI 0.657, 2.575;
p = 0.451) for Pb, respectively (Table 6).
After stratifying by the children’s gender and removing
cases with congenital malformations, the results regard-
ing PFAS, metals/elements, and ASD risk were not
changed (Additional files 3 and 4).
Association of ASD risk with the levels of sex hormones
and the combined AF-induced receptor effect biomarkers
The logistic regression analyses showed a weak associ-
ation between AF testosterone level and ASD risk (ad-
justed OR 1.002; 95% CI 1.000, 1.004; p = 0.050)
(Table 7). However, after false discovery rate correction,
this significant association did not persist (FDR qvalue =
0.437, Table 7).
We found no significant association between ASD risk
and AF-induced receptor transactivities. We noticed,
however, that the adjusted OR for the ratio of AR-AEQ/
ER-EEQ was 2.176 (95% CI 0.115, 41.15). We observed
no obvious associations between ASD risk and
dioxin-like activity (AhR-TEQ) and TH-like activity
(Table 7). Stratifying by children’s gender and removing
Table 2 Characteristics of the study population
Characteristic ASD cases (n = 75) Controls (n = 135) p value
Mother’s age at delivery (median, min-max, year) 34 (17–41) 35 (21–44) 0.218
Father’s age at delivery (median, min-max, year) 35 (19–53) 35 (20–58) 0.362
Gestational week at sampling (median, min-max) 15 (11–20) 15 (10–29) 0.426
Parity (n, %) 0.797
1st child 28 (37.30%) 48 (35.6%)
> 2nd child 47 (62.70%) 87 (64.4%)
Gestational age at birth (n, %) 0.424
Preterm (< 260 days) 7 (9.30%) 15 (11.20%)
Term (260 days–294 days) 67 (89.30%) 113 (84.30%)
Post-term (> 295 days) 1 (1.30%) 6 (4.50%)
Gender of the children (n, %) 0.731
Female 13 (17.30%) 26 (19.30%)
Male 62 (82.70%) 109 (80.70%)
Birth weight of the children (n, %) 0.521
< 2500 g 3 (4.10%) 10 (7.50%)
2500 g–4000 g 57 (77.00%) 95 (70.90%)
> 4000 g 14 (18.90%) 29 (21.60%)
Apgar score of the children (n, %) 0.952
> 7 70 (98.60%) 130 (98.50%)
< 7 1 (1.40%) 2 (1.50%)
Congenital malformation of the children (n, %) < 0.0001
No 53 (70.70%) 124 (91.90%)
Yes 22 (29.30%) 11 (8.10%)
Student t test and chi-square test were used to compare the difference between cases and controls. Italicized values indicate statistically significant
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Table 3 Levels of perfluoroalkylated substances and elements in amniotic fluid
ASD cases Control
n Median Min-max n Median Min-max p FDR (qvalue)
PFAS (ng/mL)
PFOS 37 0.61 0.61–2.98 51 1.44 0.61–4.22 0.015 0.189
PFOSA 37 0.60 0.60–13.30 51 0.60 0.60–19.00 0.152 0.638
PFOA 37 0.29 0.10–0.78 51 0.32 0.10–1.86 0.516 0.764
∑PFSA 37 1.56 1.56–15.40 51 2.60 1.56–21.70 0.011 0.189
∑PFCA 37 1.54 1.35–2.03 51 1.57 1.35–3.11 0.489 0.764
∑PFSA+∑PFCA 37 3.26 2.91–17.37 51 4.23 2.91–23.26 0.021 0.189
Elements (μg/L)
Fe 37 259.00 16.00–778.0 51 270.00 128.00–2575 0.571 0.764
Cu 37 89.15 45.62–206.10 51 100.40 53.53–223.10 0.189 0.638
Zn 37 97.90 34.69–754.5 51 102.00 30.90–1216 0.557 0.764
Se 37 4.43 2.250–7.130 51 4.55 2.980–7.27 0.758 0.861
I 37 1.88 1.88–94.68 51 1.88 1.88–195.40 0.765 0.861
Cr 37 0.75 0.16–3.85 51 0.73 0.31–2.21 0.365 0.704
Mn 37 0.65 0.65–25.89 51 0.65 0.65–5.26 0.826 0.892
As 37 1.33 1.33–6.19 51 1.33 1.33–4.96 0.328 0.704
Cd 37 0.02 0.02–1.92 51 0.02 0.02–0.14 0.648 0.795
Pb 37 0.22 0.22–2.27 51 0.22 0.22–5.30 0.526 0.764
∑PFSA perfluorosulfonated acids which was the sum of PFOS, PFHpS, PFBS, PFHxS, PFDS, and PFOSA, ∑PFCA perfluorocarboxylated acids which was the sum of
PFOA, PFHxA, PFHpA, PFNA, PFDA, PFUnA, PFDoA, and PFPeA, FDR (qvalue) false discovery rate. The difference between cases and controls was compared using
non-parametric Mann-Whitney test. Italicized values indicate statistically significant (p < 0.05 and FDR qvalue < 0.25)
Table 4 Levels of hormones and receptor transactivities in amniotic fluid
Parameter ASD case Control
n Median Min-Max N Median Min-Max p FDR (qvalue)
E2 (pg/mL) 68 287.4 78.72–2778 128 311.9 55.02–1005 0.337 0.704
Testosterone (pg/mL) 67 383.6 47.30–1393 130 366.3 80.47–1090 0.173 0.638
Testosterone/E2 ratio 66 1.49 0.21–7.41 128 1.25 0.14–4.310 0.222 0.666
ER-EEQ (pg E2/mL) 75 470.9 204.1–1308 135 545.8 149.0–1308 0.329 0.704
EDC-EEQ (pg E2/mL) 68 168.5 0.28–1226 128 214.4 2.72–1165 0.162 0.638
AR-AEQ (pg DHT/mL) 75 62.60 23.90–137.3 135 62.50 16.90–290.4 0.910 0.910
EDC-AEQ (pg DHT/mL) 67 22.56 1.000–100.4 130 28.45 1.34–274.0 0.167 0.638
AR-AEQ/ER-EEQ 75 0.13 0.02–0.48 135 0.11 0.02–0.98 0.343 0.704
EDC-AEQ/EDCs-EEQ 61 0.18 0.01–59.10 117 0.086 0.003–26.21 0.515 0.764
T3-ThEQ (ng T3/mL) 74 2.36 0.10–17.14 133 2.41 0–6.60 0.594 0.764
AhR-TEQ (pg TCDD/mL) 37 0.24 0–1.310 51 0.15 0–2.10 0.907 0.910
E2 17β-estradiol, ER-EEQ the combined effect on ER of endogenous estrogen and xeno-estrogens (EDCs) given as estradiol equivalent, EDCs-EEQ the integrated
estrogenic effect induced only by xeno-estrogens (EDCs) alone given as estradiol equivalent, DHT dihydrotestosterone, AR-AEQ the combined effect on AR of
endogenous androgens and xeno-androgens (EDCs) given as androgen equivalent, EDC-AEQ the integrated androgenic effect induced only by xeno-androgens
(EDCs) alone given as androgen equivalent, T3 L-3,5,3′-triiiodothyronine, T3-ThEQ the combined proliferation effect (PE) of endogenous thyroid and xeno-thyroid
hormone-like compounds (EDCs) given as thyroid equivalent, AhR-TEQ the combined effect on AhR of dioxin-like compounds given as TCDD equivalent, FDR
(qvalue) false discovery rate. See the “Methods” section and Table 1 for the different calculations. The difference between cases and controls was compared using
non-parametric Mann-Whitney test
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the congenital malformations did not alter the results
(Additional files 4 and 5).
Correlations between PFAS levels and combined AF-
induced receptor effect biomarkers
In general, PFAS positively correlated with the ER-EEQ
and EDC-EEQ being significant for PFOS, PFOSA,
ΣPFSA, and all tested PFAS (∑PFSA+∑PFCA). In con-
trast, PFAS inversely correlated with AR-AEQ as well as
EDC-AEQ, being significant for cases (Table 8).
Principal component analysis
Table 9 shows the loadings on the first seven principal
component (PC) variables which account for 64.6% of
the variation in the original data. Figure 2 is the graph-
ical representation of the loading on the first three PC
variables which accounts for 32.40% of the total
variation.
Summary statistics for the biomarkers with a detection
frequency > 10% used in the PCA are found in the Add-
itional file 6. Mann-Whitney test on the PCA scores for
each component revealed that only the first principal
component (PC-1), dominated by PFAS congeners, was
significantly different between cases and controls
(Additional file 7).
Logistic regression analysis showed a significantly
negative association between ASD risk and first compo-
nent (PC-1), including PFAS congeners, Cu, Fe, and
ER-EEQ, both before and after adjustment for potential
confounders (Table 10). After false discovery rate correc-
tion, the significance still persisted (adjusted OR = 0.100;
95%CI 0.016, 0.630; p = 0.014, FDR qvalue = 0.098,
Table 10). The other identified principal components did
not show significant associations with ASD risk.
After stratifying by children’s gender, the significant as-
sociation of PC-1 and ASD risk disappeared which may
due to reduced sample size (Additional file 8). When re-
moving cases with congenital malformation, similar sig-
nificant association between PC-1 and risk of ASD was
found (Additional file 9).
Discussion
The present study measured the levels of elements/
metals and POPs such as PFAS in AF and receptor
Table 5 Odds ratio and 95% confidence intervals for ASD according to PFAS in amniotic fluid
Crude Adjusteda
n (cases/controls) OR (95% CI) p n (cases/controls) OR (95% CI) p FDR (qvalue)
PFOS (ng/mL) 37/51 0.460 (0.230, 0.921) 0.028 37/50 0.410 (0.174, 0.967) 0.042 0.437
PFOSA (ng/mL) 37/51 0.913 (0.797, 1.046) 0.189 37/50 0.918 (0.789, 1.069) 0.272 0.565
PFOA (ng/mL) 37/51 0.335 (0.044, 2.559) 0.292 37/50 0.164 (0.013, 2.126) 0.167 0.437
∑PFSA (ng/mL) 37/51 0.894 (0.777, 1.028) 0.115 37/50 0.900 (0.771, 1.049) 0.178 0.437
∑PFCA (ng/mL) 37/51 0.299 (0.041, 2.160) 0.232 37/50 0.150 (0.013, 1.760) 0.131 0.437
∑PFSA+∑PFCA (ng/mL) 37/51 0.894 (0.779, 1.025) 0.107 37/50 0.896 (0.770, 1.044) 0.158 0.437
FDR (qvalue) false discovery rate. Italicized values indicate statistically significant (p < 0.05 and FDR qvalue < 0.25)
aAdjusted for children’s birth year, children’s sex, mother age at delivery, father age at child birth, birth weight, gestational week at sampling, gestational age at
birth, Apgar score, parity, and congenital malformation
Table 6 Odds ratio and 95% confidence intervals for ASD according to elements in amniotic fluid
Crude Adjusteda
n (cases/controls) OR (95% CI) p n (cases/controls) OR (95% CI) p FDR (qvalue)
Fe (μg/L) 37/51 0.999 (0.996, 1.001) 0.255 37/50 0.999 (0.997, 1.001) 0.449 0.677
Cu (μg/L) 37/51 0.991 (0.978, 1.005) 0.211 37/50 0.997 (0.981, 1.012) 0.685 0.771
Zn (μg/L) 37/51 0.999 (0.996, 1.002) 0.673 37/50 0.999 (0.995, 1.002) 0.491 0.698
Se (μg/L) 37/51 0.977 (0.649, 1.469) 0.910 37/50 1.058 (0.644, 1.740) 0.823 0.823
I (μg/L) 37/51 0.996 (0.978, 1.014) 0.674 37/50 0.981 (0.959, 1.003) 0.087 0.437
Cr (μg/L) 37/51 1.019 (0.403, 2.576) 0.968 37/50 0.377 (0.051, 2.764) 0.337 0.650
Mn (μg/L) 37/51 1.106 (0.878, 1.394) 0.393 37/50 1.065 (0.841, 1.347) 0.602 0.771
As (μg/L) 37/51 1.257 (0.856, 1.846) 0.244 37/50 1.496 (0.924, 2.424) 0.101 0.437
Cd (μg/L) 37/51 4.418 (0.099, 197) 0.444 37/50 5.935 (0.101, 349.3) 0.392 0.662
Pb (μg/L) 37/51 1.086 (0.615, 1.918) 0.776 37/50 1.300 (0.657, 2.575) 0.451 0.677
FDR (qvalue) false discovery rate
aAdjusted for children’s birth year, children’s sex, mother age at delivery, father age at child birth, birth weight, gestational age at birth, gestational week at
sampling, Apgar score, parity, and congenital malformation
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transactivities induced by AF, and explored their associ-
ation with diagnoses of child ASD. We detected PFOS
and PFOA in more than 46% of the AF samples and As,
Cd, and Pb in up to 34% of the AF samples, suggesting
that in addition to blood borne in utero exposure, the
fetus also ingests and is exposed to low levels of PFAS
and heavy metals. However, the lipophilic POPs, such as
PCBs, PBDEs, and OCPs, were not detectable in AF.
The combined biomarkers of effect such as ER-, AR-,
AhR-, and TH-like activity were determined in the AF
samples, indicating the presence of EDCs in amniotic
fluid. Compared to the controls, ASD cases showed a
different pattern regarding the AF levels of PFAS, heavy
metals, and receptor activities. Although it lacks robust,
statistically significant associations between EDCs and
ASD risk, this study suggests a role of prenatal exposure
to EDCs on the risk of ASD. But further studies are
needed, especially for their effect interfering with the
function of, e.g., sex hormone receptors such as ER and
AR.
Stein et al. reported that PFOA and PFOS were de-
tected in 86% and 32% of AF samples and suggested that
PFOA was more commonly detected in AF than PFOS
[76]. Similarly, in the present study, PFOA was detect-
able in 82% and PFOS was only detectable in 47% of the
AF samples collected during 1995–1999, suggesting that
most of the pregnant Danish women were exposed to
both PFOA and PFOS. In the present study, the median
PFOS level in AF sampling during 1995–1999 from male
offspring pregnancies in the control group was 0.61 ng/
ml, being lower than reported by Jensen et al. (1.1 ng/
ml) in their samples collected during 1980–1996 [64],
suggesting a decreasing PFOS exposure in Denmark
after 1996. However, compared to the pregnant women
in the USA during 2005–2008 [76], the AF level of PFOS
in the control group in this study (1995–1999) was
higher (1.44 vs 0.4 ng/ml) but similar for PFOA (0.32 vs
0.3 ng/ml), supporting an effective action of phase out of
PFOS and PFOA in the USA [77]. The decreasing trend
of PFOS concentrations observed in most European and
North American studies follows the phasing out in
2000–2002 of perfluorooctanesulfonyl-fluoride-based
(POSF) production by 3M [78, 79]. Similarly, a decreas-
ing trend for PFOA serum concentrations has also been
observed in several studies, indicating that exposure
pathways of these two compounds are historically linked
[79, 80]. However, the production of PFOA precursor
materials (ammonium perfluorooctanoate and fluorote-
lomer alcohols) has remained constant until 2006 [80].
Stein et al. did not detect PFOSA in the AF samples of
pregnant women in the USA [76], while PFOSA was de-
tectable in 35% of the AF samples in the present Danish
population. PFOSA is a synthetic compound used to
repel grease and water in food packing along with other
consumer applications, and it breaks down to PFOS
[81], which might partly explain the higher level of PFOS
in the present study compared to pregnant women in
the USA [76]. PFOSA was reported to have developmen-
tal neurotoxicity in vitro [82]. Although no obvious asso-
ciation was seen between PFOSA and ASD risk in this
Table 7 Odds ratio and 95% confidence intervals for ASD according to hormone level and receptor transactivity induced by
amniotic fluid
Crude Adjusteda
n (cases/controls) OR (95% CI) p n (cases/controls) OR (95% CI) p FDR (qvalue)
E2 (pg/mL) 68/128 1.000 (0.999, 1.001) 0.629 65/125 1.000 (0.999, 1.001) 0.669 0.771
Testosterone (pg/mL) 67/130 1.001 (1.000, 1.003) 0.050 64/127 1.002 (1.000, 1.004) 0.050 0.437
Testosterone/E2 66/128 1.257 (0.950, 1.664) 0.110 63/125 1.350 (0.935, 1.949) 0.110 0.437
ER-EEQ (pg E2/mL) 75/135 1.000 (0.999, 1.000) 0.358 71/132 1.000 (0.999, 1.000) 0.222 0.500
EDCs-EEQ (pg E2/mL) 68/128 0.999 (0.998, 1.000) 0.112 65/125 0.999 (0.998, 1.000) 0.089 0.437
AR-AEQ (pg DHT/mL) 75/135 0.995 (0.985, 1.006) 0.389 71/132 0.997 (0.985, 1.010) 0.650 0.771
EDCs-AEQ (pg DHT/mL) 67/130 0.989 (0.976, 1.002) 0.109 64/127 0.989 (0.974, 1.005) 0.169 0.437
AR-AEQ/ER-EEQ 75/135 1.269 (0.104, 15.479) 0.852 71/132 2.176 (0.115, 41.15) 0.604 0.771
EDCs-AEQ/EDCs-EEQ 66/128 1.022 (0.794, 1.552) 0.423 63/125 1.032 (0.974, 1.092) 0.285 0.662
T3-ThEQ (ng T3/mL) 74/133 1.094 (0.874, 1.369) 0.434 71/130 1.036 (0.806, 1.332) 0.784 0.822
AhR-TEQ (pgTCDD/mL) 37/51 0.786 (0.238, 2.589) 0.692 36/50 0.792 (0.192, 3.270) 0.747 0.822
E2 17β-Estradiol, ER-EEQ the combined effect on ER of endogenous estrogen and xeno-estrogens (EDCs) given as estradiol equivalent, EDC-EEQ the integrated
estrogenic effect induced only by xeno-estrogens (EDCs) alone given as estradiol equivalent, DHT dihydrotestosterone, AR-AEQ the combined effect on AR of
endogenous androgens and xeno-androgens (EDCs) given as androgen equivalent, EDC-AEQ the integrated androgenic effect induced only by xeno-androgens
(EDCs) alone given as androgen equivalent, T3 L-3,5,3′-triiiodothyronine, T3-ThEQ the combined proliferation effect (PE) of endogenous thyroid and xeno-thyroid
hormone-like compounds (EDCs) given as thyroid equivalent, AhR-TEQ the combined effect on AhR of dioxin-like compounds given as TCDD equivalent, FDR
(qvalue) false discovery rate. Italicized values indicate statistically significant (p < 0.05 and FDR qvalue < 0.25)
aAdjusted for children’s birth year, children’s sex, mother age at delivery, father age at child birth, birth weight, gestational age at birth, gestational week at
sampling, Apgar score, parity, and congenital malformation
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study, more research is warranted to study the effect of
PFOSA.
The testosterone and estradiol were detectable in the
AF samples. In ASD cases, the ratio of testosterone level
over E2 level in AF was non-significantly higher com-
pared to the controls. Baron-Cohen and co-workers also
reported that autism cases had higher levels of testoster-
one and other precursor steroid hormones (progester-
one, 17α-hydroxy-progesterone, and androstenedione) in
the AF samples from same cohort (HBC) [14]. The fetal
testosterone theory hypothesizes that higher levels of
testosterone in AF pushes brain development towards
improved ability to emphasize systemizing, which is a
typical male trait and diminish female trait emphasizing
[83]. An earlier study suggested that high levels of fetal
testosterone could produce behaviors relevant to those
observed for autism [84]. Auyeung et al. compared pre-
natal and postnatal testosterone and estradiol levels in
relation to autistic traits in 18- to 24-month-old chil-
dren. They found that prenatal (but not postnatal) an-
drogen exposure, coinciding with the critical period for
sexual differentiation of the brain, was associated with
the development of autistic traits in 18- to
24-month-old toddlers. This suggests that prenatal,
organizational effects of androgen hormones influence
the development of autistic traits in later life [85]. Other
studies reported that estrogen can be protective while
androgens potentiate ASD [86, 87], supporting our ob-
servation of lower levels of endogenous estrogen E2 and
higher endogenous androgen testosterone found in ASD
cases. Furthermore, in support to our study, a higher ra-
tio of testosterone to estradiol in AF was suggested to be
associated with ASD [58],
EDCs deserve consideration as candidate risk factors
for ASD because of their potential to alter hormonal axis
functions that play an important role in neurodevelop-
ment. However, few studies have examined the link be-
tween EDC exposure, especially for PFAS, and the risk
of ASD or autistic behaviors. A cross-sectional study
suggested that there might be a protective association
between exposure to PFAS and cognition in older adults
[88]. A prospective study showed better cognitive
Table 8 The correlation among PFAS levels in amniotic fluid and receptor transactivity induced by AF
ER-EEQ EDC-EEQ AR-AEQ EDC-AEQ T3-ThEQ AhR-TEQ
n rs p n rs p n rs p n rs p n rs p n rs p
ASD cases
PFOS 37 0.522 0.001 30 0.246 0.189 37 − 0.258 0.124 30 − 0.466 0.009 34 0.145 0.398 37 0.097 0.569
PFOSA 37 0.237 0.158 30 0.199 0.292 37 − 0.391 0.017 30 − 0.163 0.390 36 − 0.038 0.825 37 0.140 0.410
PFOA 37 0.225 0.180 30 0.317 0.087 37 0.007 0.968 30 − 0.399 0.029 34 0.039 0.822 37 0.125 0.462
∑PFSA 37 0.332 0.045 30 0.158 0.403 37 − 0.305 0.066 30 − 0.310 0.095 34 − 0.026 0.882 37 0.100 0.555
∑PFCA 37 0.225 0.180 30 0.317 0.087 37 0.007 0.968 30 − 0.399 0.029 34 0.039 0.822 37 0.125 0.462
∑PFSA+∑PFCA 37 0.343 0.038 30 0.330 0.075 37 − 0.194 0.249 30 − 0.318 0.087 34 − 0.005 0.978 37 0.138 0.417
Controls
PFOS 51 0.156 0.276 44 0.273 0.073 51 − 0.082 0.565 46 − 0.010 0.947 48 − 0.004 0.979 51 − 0.065 0.649
PFOSA 51 0.220 0.121 44 0.356 0.018 51 − 0.160 0.263 46 − 0.108 0.476 49 − 0.221 0.127 51 − 0.273 0.1053
PFOA 51 0.104 0.469 44 0.097 0.530 51 − 0.002 0.989 46 0.048 0.751 48 0.209 0.150 51 0.148 0.300
∑PFSA 51 0.321 0.021 44 0.442 0.003 51 − 0.160 0.263 46 − 0.071 0.641 48 − 0.186 0.202 51 − 0.253 0.074
∑PFCA 51 0.100 0.487 44 0.093 0.548 51 − 0.005 0.974 46 0.051 0.736 48 0.203 0.161 51 0.142 0.322
∑PFSA+∑PFCA 51 0.332 0.017 44 0.438 0.003 51 − 0.146 0.305 46 − 0.047 0.757 48 − 0.148 0.309 51 − 0.217 0.125
All
PFOS 88 0.305 0.004 74 0.251 0.031 88 − 0.182 0.090 76 − 0.085 0.465 85 0.18 0.871 88 0.015 0.891
PFOSA 88 0.224 0.036 74 0.304 0.009 88 − 0.258 0.015 76 − 0.114 0.328 85 − 0.141 0.197 88 − 0.120 0.267
PFOA 88 0.194 0.070 74 0.212 0.070 88 − 0.031 0.777 76 − 0.127 0.274 82 0.117 0.285 88 0.145 0.178
∑PFSA 88 0.342 0.001 74 0.354 0.02 88 − 0.259 0.015 76 − 0.114 0.328 82 − 0.119 0.278 88 − 0.106 0.326
∑PFCA 88 0.191 0.074 74 0.210 0.073 88 − 0.033 0.758 76 − 0.123 0.288 82 0.115 0.294 88 0.142 0.187
∑PFSA+∑PFCA 88 0.361 0.001 74 0.398 < 0.001 88 − 0.218 0.042 76 − 0.103 0.374 82 − 0.088 0.423 88 − 0.065 0.545
ER-EEQ the combined effect on ER of endogenous estrogen and xeno-estrogens (EDCs) given as estradiol equivalent, EDC-EEQ the integrated estrogenic effect
induced only by xeno-estrogens (EDCs) alone given as estradiol equivalent, DHT dihydrotestosterone, AR-AEQ the combined effect on AR of endogenous
androgens and xeno-androgens (EDCs) given as androgen equivalent, EDC-AEQ the integrated androgenic effect induced only by xeno-androgens (EDCs) alone
given as androgen equivalent, T3 L-3,5,3′-triiiodothyronine, T3-ThEQ the combined proliferation effect (PE) of endogenous thyroid and xeno-thyroid hormone-like
compounds (EDCs) given as thyroid equivalent, AhR-TEQ the combined effect on AhR of dioxin-like compounds given as TCDD equivalent, rs, Spearman’s rho
correlation coefficient. Italicized values indicate statistically significant (p < 0.05)
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abilities among children with higher prenatal PFOA ex-
posure [89], and increasing maternal blood PFOA con-
centrations were reported to be associated with fewer
autistic behaviors [12]. Other studies did not find posi-
tive correlation between maternal PFAS exposure and
attention-deficit hyperactivity disorder (ADHD) or ASD
[90, 91]. Our previous study showed that PFAS, such as
PFOS and PFOA, elicited estrogenic and
anti-androgenic potential in vitro and ex vivo [23, 92]. In
support, in the present study, we found PFAS levels
positively correlated to the combined xenoestrogenic ef-
fect (EDC-EEQ) while inversely correlated to the com-
bined xenoandrogenic effect (EDC-AEQ). The fetus
seems to be uniquely sensitive to the anti-androgenic ef-
fect of EDCs. Given their anti-androgenic properties,
one could hypothesize that PFAS exposure might reduce
the risk of autism. This observation might partly explain
the inverse association between PFAS level in AF and
ASD risk observed in the present study. Moreover, in
vitro studies report that PFOA and PFOS are partial ag-
onists of the human peroxisome proliferator-activated
receptor-γ (PPAR-γ), and PPAR-γ activation may be
neuroprotective [93].
In the present AF study, we observed the ratio of
AR-AEQ/ER-EEQ was non-significantly positively asso-
ciated with ASD risk. AR-AEQ/ER-EEQ represents the
proportion of total combined androgenic effect contrib-
uted by androgen and EDCs to the total combined estro-
genic effect contributed by endogenous estrogen and
EDCs. Hence, it is worthy to further study whether
EDCs play a role in the development of ASD together
with endogenous hormones.
Table 9 Rotated factor loading of components identified by principal component analysis (PCA)
Interpreted biomarker component Biomarker name Factor loadinga Explained variance (%) Explained variance cumulative (%)







PC-2 AhR-TEQ 0.834 10.08 22.35
Fe 0.758
AR-AEQ 0.658













PC-6 Se 0.746 7.76 56.93
As 0.691
Cu 0.480
PC-7 testosterone 0.818 7.71 64.63
ER-EEQ 0.622
PC principal component
aFactor loadings are the correlation coefficients between the original variables (levels of chemicals and receptor transactivities) and the extracted components.
Variable levels are sorted by the size of the loading coefficients. Variable levels with factor loading below |0.30| are not listed
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Fig. 2 (See legend on next page.)
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Existing studies of autism suggest that prenatal metal
exposure may be related to autism [94]. Exposure to Pb
during neurodevelopment has significant effects on neu-
robehavioral and intellectual performance, also resulting
in attention, hyperactivity, and learning disorders [17,
95, 96]. Lead poisoning has been suggested as a possible
risk factor for autism, as Pb blood levels of autistic chil-
dren have been reported to be significantly higher than
those of healthy children [97]. Previous studies have
shown that perinatal exposure to Mn, Pb, and Cd from
air pollution increased ASD risk [42]. In the present
study, we observed that As and Pb levels in AF tend to
be positively associated with ASD risk, suggesting the
possible role of prenatal exposure to toxic metals in the
ASD development. However, given that these metals
were detectable in less than 34% of the AF samples,
more studies are needed to explore the role of prenatal
heavy metal exposure on the risk of ASD.
There are several strengths in this study. First, the
measurements of chemicals and receptor transactivities
were based on the AF samples collected in pregnancy
from routine amniocentesis prior to the assessment of
the outcome in the offspring. Study participants were se-
lected from a well-defined nation-wide pregnancy cohort
and case-control matched by gender, year of birth, and
maternal age. The outcome measures were clinical diag-
noses using standardized diagnostic criteria (ICD classi-
fication), and diagnoses of autism in the psychiatric
registry have been shown to have high validity [50]. Sec-
ondly, many exposure parameters were determined sim-
ultaneously in the single AF sample. This minimizes bias
from differential misclassification. Thirdly, for the very
first time, the combined mixture effect of EDCs was de-
termined in AF. Moreover, the measurements of recep-
tor transactivities consider the combined effect of EDC
mixtures and endogenous hormones in AF. However,
multiple testing issue should be addressed. We used the
Benjamini-Hochberg method to control false discovery
rate (FDR) and found that the significant association
with the most individual exposure biomarker variables
did not persist and thus cannot exclude a chance
finding.
People are exposed to the mixture of different sub-
stances simultaneously, and therefore, it is important to
assess the effect of actual combined effect of a mixture
and principal component analysis (PCA) might provide
the possibility to address this issue. The PCA extracts ef-
fective information from multidimensional data and is a
powerful method to reduce the large number of highly
correlated variables, so that results in fewer variables to
be examined statistically. PCA reduced the false positive
results by reducing the number of variables. Further-
more, PCA allows for the determination of which vari-
ables have common patterns of variances. PCA has been
widely used for epidemiological studies [69]. To this
aim, we further used PCA to extract the integrated prin-
cipal component and analyzed the association of identi-
fied components and ASD risk. We observed a
significantly negative association of ASD risk and the
first principle component (PC-1), dominated by PFAS
congeners and including Cu, Fe, and ER-EEQ, and the
association persisted after corrected by FDR. Although it
is difficult to interpret this observation clinically, this ob-
servation might suggest a role of combined effect of
Table 10 Odds ratio and 95% confidence intervals for ASD according to PCA components
Crude Adjusteda
n (cases/controls) OR (95% CI) p n (cases/controls) OR (95% CI) p FDR (qvalues)
PC-1 29/44 0.236 (0.092, 0.607) 0.003 29/44 0.100 (0.016, 0.630) 0.014 0.098
PC-2 29/44 0.793 (0.449, 1.398) 0.422 29/44 0.943 (0.456, 1.948) 0.873 0.961
PC-3 29/44 1.180 (0.733, 1.897) 0.496 29/44 1.059 (0.538, 2.082) 0.868 0.868
PC-4 29/44 1.167 (0.724, 1.880) 0.526 29/44 1.027 (0.363, 2.903) 0.961 0.961
PC-5 29/44 1.064 (0.668, 1.695) 0.793 29/44 1.431 (0.810, 2.531) 0.218 0.763
PC-6 29/44 1.061 (0.664, 1.697) 0.804 29/44 1.258 (0.661, 2.393) 0.485 0.849
PC-7 29/44 1.25 (0.773, 2.025) 0.363 29/44 1.354 (0.662, 2.767) 0.407 0.849
PC principal component, FDR (qvalue) false discovery rate. For component of PC-1~PC-7, see Table 9. Italicized values indicate statistically significant (p < 0.05 and
FDR qvalue < 0.25)
aAdjusted for children’s birth year, children’s sex, mother age at delivery, father age at child birth, birth weight, gestational week at sampling, gestational age at
birth, Apgar score, parity, and congenital malformation
(See figure on previous page.)
Fig. 2 Plots of rotated factor loading of the three largest principal components (PCs) identified by principal component analysis (PCA). The
percentage of variation (%) explained by each PC variable is presented in parenthesis in the axis label. a Plots PC-1 loading against PC-2. b Plots
PC-1 against PC-3. c Plots PC-2 against PC-3. Red dots are main component of PC-1, blue dots are main components of PC-2, and orange dots
are main components of PC-3. White dots indicate lower factor loading (< |0.3|). For the detail on factor loading scores, see Table 9
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PFAS, Cu, Fe, and estrogenic EDCs on the risk of ASD
and further studies are needed to explore the combined
effect of substances which the fetus are exposed to sim-
ultaneously. It has been shown that the different PFAS
congeners are highly correlated. Our previous studies
have shown PFAS elicited the estrogenic effect and
anti-androgenic effect [23, 92]. This was further con-
firmed by the result regarding the correlation of PFAS
and receptor transactivities in the present study. There-
fore, it is reasonable that PFAS congeners and ER-EEQ
were identified in the same component. It is not clear
why nutrients Cu and Fe were gathered together with
PFAS and ER-EEQ. More studies are needed to explore
whether it is because of similar exposure pathway.
In the present study, we included congenital malforma-
tion cases in the data set. Given the genetic factors that
contributed ASD, we performed the sensitive analysis by
further adjustment of congenital malformation and ex-
cluding cases with congenital malformation. The results
did not change significantly because congenital malforma-
tion of cases and non-cases did not have significantly dif-
ferent levels in the exposure variables of interest.
This study has also some limitations. Firstly, the sam-
ple size in the present study was small due to toxic effect
of rubber tube plugs used in connection with some of
the cell culture analyses, and volume restriction for the
parameters measured in each AF samples. The statistical
power is thus expected to be low, and this might explain
the lack of statistical significance. Because this study is
the first study to explore the association of AF levels of
PFAS and the combined EDC and endogenous hormone
ex vivo receptor transactivities and ASD risk, it is hard
to perform priori power calculation at the design stage.
Nevertheless, we calculated the statistical power based
on the average levels of exposure variables and the
power ranged from 5.0 to 68.6% for individual exposure
biomarkers. However, by using data reduction technique
principal component analysis (PCA), the power is high
for the first two identified principal components (PC-1
98.5%, PC-2 99.0%, respectively). Secondly, studies have
reported that PFAS reduced fecundity in humans [98,
99]. Therefore, it is possible that PFAS exposure at a
level that reduces fetal survival, especially in high-risk fe-
tuses susceptible to neurological disorders such as ASD,
could appear to have a null or even protective effect on
adverse neurobehavioral outcomes in children in obser-
vational studies affected by selection bias, since only live
born children can be followed-up and examined. All psy-
chiatric and somatic diagnoses were retrieved from
nation-wide registers (DPCR and DNHR), and no infor-
mation on autistic clinical symptomatology was available
to validate the diagnoses. However, other studies have
shown that within the DPCR the validity ratio for child-
hood autism cases is 94.0% for 1990–1999 [50]. Thirdly,
the measurements of chemicals and biomarkers of ef-
fects such as the combined (endogenous hormones and
EDCs) induced receptor transactivities were done from a
historic collection of the AF samples stored over several
years at − 20 °C. However, for the cohort analyzed in this
study (born between 1995 and 1999), storage
time-dependent changes are unlikely to be a major issue
[14]. The prevalence estimate of autism within this am-
niocentesis cohort (0.72%) is consistent with prevalence
estimates of autism in the Danish population during the
same time period [4]. Thus, although these results are
derived from a selected sample, they may be representa-
tive of what would be expected in the general popula-
tion. In the future, it is necessary to sample more
representatives from the general population and collect
more data regarding risk factors for fetal survival to fur-
ther explore the integrated effect of EDCs on the devel-
opment of autism. Finally, AF is an aqueous solution
with suspended desquamated fetal epithelial cells. As
gestation progresses, other organic materials including
fetal feces and urine are also present. AF contains ap-
proximately equal parts of organics (proteins, carbohy-
drates, fats, enzymes, hormones, pigments) and
inorganics. In human serum, some PFAS binds to circu-
lating proteins (serum albumin) [100]. It is possible that
some PFAS congeners were removed from the AF sam-
ple during its initial processing for clinical care purposes
when the fluid was centrifuged and the precipitated cells
retained for genetic testing [76]. Thus, the concentra-
tions of PFAS in the AF samples might be underesti-
mated and blur their effect on ASD.
Conclusions and perspectives
The present study showed that environmental endocrine
disrupting chemicals (EDCs), such as PFAS, some metals,
and their biological activities can be detected in amniotic
fluid, indicating that EDCs can cross the placenta and in-
crease the potential fetal exposure to these environment
contaminants. EDCs might modify ASD risk by influencing
the hormone receptor function. The inverse association be-
tween PFAS levels and ASD risk might relate to a weak es-
trogenic activities and anti-androgenic activities of single
PFAS congener observed in vitro. The observed tendency
of positive association between the ratio of combined an-
drogenic effect to the combined estrogenic effect and ASD
risk needs further studies to explore the role of combined
effect of EDCs together with endogenous hormones in the
development of ASD. However, individual variability in
genetic susceptibility can influence responses to environ-
mental toxicants and contribute to increase disease vulner-
abilities. Several studies have reported that some individuals
with ASD express polymorphisms in genes involved in the
detoxification of environmental pollutants and these genes
have been termed “environmental response genes.” More
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than 100 environmental response genes may contribute to
ASD risk [101, 102]. Therefore, it is necessary to study the
role of gene polymorphisms and gene environment inter-
action in the development of ASD.
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